762227-03-2

Upstream product

• 250215-08-8 N²-benzyloxycarbonyl-N⁵-(3-phenyloxaziridinyl)-L-ornithine 
• 250215-07-7 N₂-benzyloxycarbonyl-N₅-benzylidene-L-ornithine 
• 250215-09-9 C₂₀H₂₂N₂O₅ 
• 2640-58-6 Nα-benzyloxycarbonyl-L-ornithine 

Downstream Products

• 250215-11-3 N²-benzyloxycarbonyl-N⁵-acetyl-N⁵-O-acetyl-L-ornithine 

Relevant academic research and scientific papers

ANTIBODY DRUG CONJUGATES

The present invention pertains to an antibody-drug conjugate comprising an antibody, ferric iron and at least one drug molecule,and to a pharmaceutical composition comprising the antibody-drug conjugate. The invention further relates to the use of the antibody-drug conjugates in the treatment of diseases, e.g. cancer.

Practical synthesis of hydroxamate-derived siderophore components by an indirect oxidation method and syntheses of a DIG-siderophore conjugate and a biotin-siderophore conjugate

A practical large-scale synthesis of hydroxamate-derived siderophore components (30 and 40) that utilizes an efficient indirect oxidation method is described and applied to the syntheses of nonradioactive labeled siderophores. Oxidation of imines derived from L-ornithine (17) and its tripeptide (19) afforded oxaziridines that were isomerized to stable nitrones (16 and 18). Acid-catalyzed hydrolysis of nitrones provided hydroxylamines that were converted to the desired hydroxamic acids (30 and 40) suitable for constructing siderophore-drug conjugates (2). The entire synthetic sequence required no chromatographic separation. DIG- and biotin-labeled ferrichrome analogues designed to detect and isolate ferrichrome receptors in various microbes were also synthesized.